Biodexa Pharmaceuticals Plc Files 6-K with Financial Data

TL;DR

Biodexa Pharma (BDRX) dropped its Q2 2024 financials in a 6-K filing, showing balance sheet details.

AI Summary

Biodexa Pharmaceuticals Plc filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the six months ended June 30, 2024, and comparative periods. Key financial statement items like Share Capital, Share Premium, Merger Reserve, Warrant Reserve, and Retained Earnings are detailed for fiscal years 2022 and 2023, and the first half of 2024.

Why It Matters

This filing provides investors with updated financial statements, allowing them to assess the company's financial health and performance trends over the reported periods.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) that provides historical financial data and does not contain new operational or strategic announcements.

Key Numbers

• 2024-06-30 — Reporting Period End Date (Financial data pertains to this date and prior periods.)
• 2023-12-31 — Prior Year End Date (Comparative financial data is provided for this date.)
• 2022-12-31 — Prior Year End Date (Comparative financial data is provided for this date.)

Key Players & Entities

• Biodexa Pharmaceuticals Plc (company) — Filer
• 0001643918 (company) — Central Index Key
• 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
• Midatech Pharma Plc (company) — Former Company Name

FAQ

Key Financial Figures

• $17 million — posis ("FAP") together with access to a $17 million grant. Six month data of eRapa in FAP
• $6.05 million — 1 FINANCIAL HIGHLIGHTS Receipt of $6.05 million in gross proceeds from the exercise of
• $5.0 million — million. Post period end: Receipt of $5.0 million in gross proceeds from a Registered Dir
• $17 million — a, a Phase 3 ready asset with access to $17 million of non-dilutive grant funding, is an en
• $31.5 million — also responsible for up to an aggregate $31.5 million in sales milestones within the first si
• $10.0 million — l indications. There is also a one-time $10.0 million milestone payable upon cumulative net s
• $1.0 billion — ne payable upon cumulative net sales of $1.0 billion. Further, we are also obligated to pay
• $0.25 million — favour of the Company in the amount of $0.25 million was forgiven. We also made an additiona
• $0.5 million — as forgiven. We also made an additional $0.5 million payment which was used for a match to a
• $17.0 million — he CPRIT. Emtora had secured a grant of $17.0 million from CPRIT to support the Phase 3 study
• $7.5 m — was expected to fund the match of up to $7.5 million, being 50% of the remaining CPRIT
• $3.0 million — Phase 2 study, which is supported by a $3.0 million non-dilutive grant from the National Ca
• $1.50 — ries F warrants at an exercise price of $1.50 (reduced from $2.20) per ADS. In consi
• $2.20 — n exercise price of $1.50 (reduced from $2.20) per ADS. In consideration for the imm
• $2.50 — ve years and one year, respectively, at $2.50 each. July 2024 Registered Direct Offe

Filing Documents

• v9232406k.htm (6-K) — 820KB
• ex99_1rdchart.jpg (GRAPHIC) — 72KB
• 0001214659-24-016740.txt ( ) — 4502KB
• bdrx-20240630.xsd (EX-101.SCH) — 53KB
• bdrx-20240630_cal.xml (EX-101.CAL) — 47KB
• bdrx-20240630_def.xml (EX-101.DEF) — 101KB
• bdrx-20240630_lab.xml (EX-101.LAB) — 227KB
• bdrx-20240630_pre.xml (EX-101.PRE) — 199KB
• v9232406k_htm.xml (XML) — 969KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 June 30,2024 For the month of September 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point , Caspian Way Cardiff , CF10 4DQ , United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F o Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o The information included in this report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333 - 267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SUBMITTED HEREWITH Attached to the Registrant's Form 6-K filing for the month of September 2024 is: Exhibit No. Description 99.1 Press Release, dated September 26, 2024, entitled "Interim results for the sixth months ended 30 June 2024". 101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH INLINE XBRL Taxonomy Extension Schema Document. 101.DEF INLINE XBRL Taxonomy Extension Calculation Linkbase Document. 101.LAB INLINE XBRL Taxonomy Extension Label Linkbase Document. 101.PRE INLINE XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC Date: September 26, 2024 By: /s/ Stephen Stamp Stephen Stamp Chief Executive Officer and Chief Financial Officer Exhibit 99.1 September 26, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2024 which will also be made available on the Company's website at www.biodexapharma.com OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2024: Exclusive worldwide licensing of eRapa, a Phase 3 ready asset with a lead indication of Familial Adenomatous Polyposis ("FAP") together with access to a $17 million grant. Six month data of eRapa in FAP showing an 83% non-progression rate and a statistically significant reduction on overall polyp burden, announced at the Digestive Disease Week scientific meeting in Washington D.C. 12 month data of eRapa in FAP showing a 75% non-progression rate and median overall decrease in polyp burden of 17%, presented at the bi-annual InSIGHT scientific meeting in Barcelona. 12 month overall survival of patient #1 in the Company's MAGIC-G1 Phase 1 study of MTX110 in recurrent Glioblastoma ("rGBM"). 16.5 months overall survival of patients in a Phase 1 study of MTX110 in Diffuse Midline Glioma, subsequently presented at the International Symposium on Pediatric Neuro-oncology (ISPNO 2024). Allowance by the US Patent and Trademark Office of Family 13 ("Prevention of Pancreatic Cell Degeneration"), a key component of tolimidone exclusivity. Post period end: Approval by Health Canada to proceed with a Phase 2a dose confirmation study of tolimidone in Type 1 diabetes to be conducted by the University of Alberta Diabetes Institute. An update on the status of cohort A in the MAGIC-G1 study: patients #1 and #2 have deceased with overall survival (OS) since start of treatment of 12 months and 13 months, respectively. Patients #3 and #4 remain alive with progression free survival (PFS) since the start of treatment of 6 and 9 months, respectively and OS thus far of 12 and 11 months respectively. 1 FINANCIAL HIGHLIGHTS Receipt of $6.05 million in gross proceeds from the exercise of certain Series E and Series F warrants to purchase 4.4 million ADSs. The warrant inducement included a reduction in exercise price and issuance of replacement Series G and Seri

View Full Filing

View this 6-K filing on SEC EDGAR